3 ms·

Pharma companies don't feel any embarrassment because it's really not much of a priority for them. Protein structure determination simply isn’t a rate-limiting

• dekhn 6y ago
  That is true but every pharma has a structural biology department that solves product-related crystal structures with the intent of using that data to speed development. It's an established thing, $100+M/year budget per company. Generally well-respected and considered some of the most important IP the company can generate. They also have theory groups which try to do structure prediction and drug docking but I don't think those groups get any respect inside the companies any more.